VTRS Jan 2026 20.000 call
- PR Newswire
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
- Zacks
Here's Why You May Invest in Theravance (TBPH) Stock Now
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
- ACCESSWIRE
Viatris Named to TIME’s World’s Most Sustainable Companies 2024 List
PITTSBURGH, PA / ACCESSWIRE / June 25, 2024 /Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024. This recognition is presented ...
